Why the study?
Does metformin prevent isoproterenol-induced cardiac hypertrophy in mice?
Does metformin prevent isoproterenol-induced cardiac hypertrophy in mice?
Metformin partially inhibits isoproterenol-induced cardiac hypertrophy in mice, likely through attenuation of oxidative stress rather than chronic AMPK activation in the heart.
Answers are grounded in this paper and cite their sources.
Should not change clinical practice; leaves open whether metformin's effects translate beyond this animal model.
The present study examined whether metformin treatment prevents isoporterenol-induced cardiac hypertrophy in mice. Chronic subcutaneous infusion of isoproterenol (15 mg/kg/24 h) for 1 week using an osmotic minipump induced cardiac hypertrophy measured by the heart-to-body weight ratio and left ventricular posterior wall thickness. Cardiac hypertrophy was accompanied with increased interleukin-6 (IL-6), transforming growth factor (TGF)-β, atrial natriuretic peptide (ANP), collagen I and III, and matrix metallopeptidase 2 (MMP-2). Coinfusion of metformin (150 mg/kg/24 h) with isoproterenol partially inhibited cardiac hypertrophy that was followed by reduced IL-6, TGF-β, ANP, collagen I and III, and MMP-2. Chronic subcutaneous infusion of metformin did not increase AMP-activated protein kinase (AMPK) activity in heart, although acute intraperitoneal injection of metformin (10 mg/kg) increased AMPK activity. Isoproterenol increased nitrotyrosine levels and mRNA expression of antioxidant enzyme glutathione peroxidase and metformin treatment normalized these changes. These results suggest that metformin inhibits cardiac hypertrophy through attenuating oxidative stress.
No takes yet. Share an insight, caveat, or question.
Cha et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: